Skip to content

Early treatment and interruption makes no difference to disease progression, study finds

European activists claim Pfizer's CCR5 antagonist trial unnecessarily putting most vulnerable at risk; US activists disagree

Trizivir approved in Europe

European activists and drug authority agree on need for single early access system

Triple PI salvage therapy

What to do with nelfinavir?